Lineage Cell Therapeutics, Inc. Business Combination, Consideration Transferred, Equity Interests Issued and Issuable
Lineage Cell Therapeutics, Inc. (LCTX) had Business Combination, Consideration Transferred, Equity Interests Issued and Issuable of $3.10 million as of 2017-06-06, per its 10-Q filed 2017-11-09.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable · last filed 2017-11-09
- Lineage Cell Therapeutics, Inc. business combination, consideration transferred, equity interests issued and issuable for fiscal 2012 was $1.80M.
| Period end | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 12 month |
|---|---|---|
| 2017-06-06 | $3.10M 10-Q · filed 2017-11-09 | |
| 2012-12-31 | $1.80M 10-K · filed 2015-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |